Low Philip S 4
4 · Cortexyme, Inc. · Filed May 23, 2022
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Low Philip S
Director
Transactions
- Award
Common Stock
2022-05-19+455,309→ 455,309 total - Award
Common Stock
2022-05-19+63,974→ 63,974 total(indirect: By Trust) - Award
Stock Option (right to buy)
2022-05-19+22,058→ 22,058 totalExercise: $3.30Exp: 2032-05-18→ Common Stock (22,058 underlying)
Footnotes (2)
- [F1]On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
- [F2]The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.